Category: Treatment


Promising Uveal Melanoma Research Advances

By Cody R. Barnett, MRA Director of Communications | 26 October 2021 In News, Science, Treatment

Uveal melanoma, often called ocular melanoma or just eye melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. As is true with other rare subtypes, we know far less about what causes uveal melanoma, how it progresses, and how it can be...

Read More


Challenge Accepted: MRA 2020 - 2021 Annual Report

19 October 2021 In Allies & Partnerships, Melanoma Stories, News, Policy, Prevention, Science, Treatment

This was a year like no other. COVID-19 presented new challenges that required new ways of thinking. At MRA, confronting challenges is part of our DNA. We never stop challenging ourselves, no matter the odds or obstacles, in pursuit of conquering melanoma and saving lives.

Read More


The Next Frontier of Combination Immunotherapy: Maximizing the Benefits & Reducing Harms

15 September 2021 In Science, Treatment

Every general knows that the best way to successfully win a war is to deploy multiple weapons with different targets. This strategy was first used in cancer to conquer childhood leukemias with combination chemotherapy and now is being put to the test in melanoma by combining multiple checkpoint inhibitors, as...

Read More


Practical Recommendations for Surviving and Thriving Despite Melanoma

4 August 2021 In Treatment

Most experts, including the National Cancer Institute, say that a person becomes a survivor from the moment they learn of their cancer diagnosis – for the rest of their life. Get practical tips and strategies to live well with melanoma based on an expert panel conversation, led by Dr. Sapna Patel of the University of Texas M.D. Anderson Cancer Center.

Read More


Full Sails Ahead: Immunotherapy Shows Continued Survival Benefit for Patients Facing Advanced Melanoma

By Cody R. Barnett, MRA Director of Communications | 28 July 2021 In News, Science, Treatment

After carefully following patients enrolled in Checkmate 067 over the last 6.5 years, he and the research team determined that 49% of patients treated with Opdivo + Yervoy were alive at 6.5 years and 77% of these patients remained treatment-free. This represents the longest reported median overall survival in a phase 3 melanoma clinical trial – ever.

Read More


Biomarkers: What They Are, Why They Matter, and Where They are Going

22 July 2021 In Allies & Partnerships, Science, Treatment

The melanoma treatment field has been rewarded recently with an abundance of riches. But all these exciting new treatment options for patients can also create complexity and confusion. Fortunately, help is on the way in the form of biomarkers — molecular or cellular indicators for whether a patient is likely to respond or is currently responding to their therapy, or whether they are likely to have a recurrence of their cancer.

Read More


2021 AACR and ASCO Melanoma Highlights

By Marc Hurlbert, Ph.D., MRA Chief Science Officer | 29 June 2021 In News, Science, Treatment

Over the last few months, thousands of scientists and physicians from around the globe gathered virtually for two of the largest cancer research conferences – AACR and ASCO. Melanoma research advances were showcased at both events and it’s an exciting time with numerous presentations of clinical trials for new melanoma treatments. Here we highlight some of the most exciting results from both conferences.

Read More


New Immunotherapy Drugs Targeting LAG-3 Show Great Promise

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 23 June 2021 In News, Science, Treatment

Researchers presented a series of highly encouraging clinical trial results at the recent American Society for Clinical Oncology (ASCO) annual meeting that suggest that new drugs targeting the protein LAG-3 – developed by BMS and Regeneron – may be an important addition to the current treatment arsenal.

Read More


Averting and Treating Immune-related Adverse Events Associated with Checkpoint Immunotherapies

14 June 2021 In Science, Treatment

Checkpoint inhibitors are therapies that empower the immune system to kill cancer cells. However, sometimes immune-related adverse events (irAE) can also occur as a result. To help overcome this challenge, MRA has issued a number of research grants, including some in partnership with the American Cancer Society (ACS) and the Society for Immunotherapy of Cancer (SITC), to support an array of approaches.

Read More


Advancing Melanoma Research in Times of Uncertainty

By Cody R. Barnett, MRA Director of Communications | 9 June 2021 In Allies & Partnerships, Melanoma Stories, Policy, Prevention, Science, Treatment

Each year, the annual MRA Scientific Retreat brings hundreds of people from across the melanoma research ecosystem together to exchange ideas, report on scientific progress, celebrate achievements, and mourn the losses. In these ways, the 2021 Retreat was no different.

Read More


Login

×